History | Mirikizumab for treating moderately to severely active ulcerative colitis | Guidance | NICE

History

Documents created during the development process.

Expected publication

Equality Impact Assessment (Guidance development) (PDF 147 KB)

Published:

22 September 2023
Supporting documentation Register of interests (PDF 126 KB)

Published:

29 November 2023

Final draft guidance

Final draft guidance
Final appraisal document (PDF 169 KB)

Published:

22 September 2023
Committee papers (PDF 6.79 MB)

Published:

22 September 2023
Public committee slides (PDF 795 KB)

Published:

22 September 2023

Invitation to participate

Draft scope and provisional stakeholder list comments table (post-referral) (PDF 234 KB)

Published:

25 August 2022
Final stakeholder list (PDF 158 KB)

Published:

25 August 2022
Equality Impact Assessment (Guidance development) (PDF 125 KB)

Published:

25 August 2022
Final scope (PDF 216 KB)

Published:

02 September 2022

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Draft scope post referral (PDF 216 KB)

Published:

28 June 2022
Draft matrix post referral (PDF 158 KB)

Published:

28 June 2022